More drugs qualifying for FDA accelerated review, driven by non-innovative medicines
Over the past 30 years, more drugs qualified for accelerated approval programmes with the FDA despite not being first-in-class medicines.
Source: Wikimedia Commons
The US Food and Drug Administration (FDA) has four programmes to accelerate the development or approval of drugs addressing unmet medical needs or treating serious conditions. However, their reliance on potentially less robust data makes them controversial.
Researchers at Brigham and Women’s Hospital and Harvard Medical School, Boston, evaluated the use of the FDA’s expedited drug development and review programmes between 1987 and 2014. During the course of the study period, 774 drugs were approved. There was a significant increase in the number of drugs qualifying for one of these programmes, with a 2.4% increase each year in the proportion of qualifying drugs (P=0.009).
The analysis shows that this trend was linked to approval of non first-in-class drugs, “which are less likely to be innovative or clinically transformative therapeutics”, say the authors in the BMJ (2015;351:h4633).
Citation: Clinical Pharmacist DOI: 10.1211/PJ.2015.20069471
Recommended from Pharmaceutical Press
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00
Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.£47.00
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£262.50
Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.£38.00